Parexel Early Phase Clinical Unit — Baltimore, Maryland

Parexel Early Phase Clinical Unit is a clinical research site located in Baltimore, Maryland, United States 21225.

Crixeo Health Trust Score: 72/100 (FAIR). This profile has not yet been claimed by the site owner.

Parexel Early Phase Clinical Unit has participated in 5 clinical trials.

Therapeutic areas: Diphtheria, Healthy Volunteers, Pharmacokinetics of Repaglinide.

Sponsors: MassBiologics, Elixiron Immunotherapeutics (Hong Kong) Ltd., Astellas Pharma Global Development, Inc..

Sponsor Feasibility Report

Trust Score: 72/100. Verification status: Crixeo Accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Parexel Early Phase Clinical Unit?

Parexel Early Phase Clinical Unit has a Crixeo Trust Score of 72/100 (FAIR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Parexel Early Phase Clinical Unit conducted?

Parexel Early Phase Clinical Unit has 5 clinical trials on record. Their work covers Diphtheria, Healthy Volunteers, Pharmacokinetics of Repaglinide.

Is Parexel Early Phase Clinical Unit accredited by Crixeo Health?

Yes — Parexel Early Phase Clinical Unit holds Crixeo Accreditation, the quality standard for clinical research sites. Accredited sites have verified compliance documents, strong patient reviews, and sponsor transparency.

Can I submit a review or complaint about Parexel Early Phase Clinical Unit?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.